Genentech Fights FDA's Downgrade Of Avastin
Genentech Inc. has announced that it plans to appeal the U.S. Food and Drug Administration's finding that the blockbuster cancer drug Avastin has not been proven safe and effective in treating...To view the full article, register now.
Already a subscriber? Click here to view full article